Aims Zolmitriptan (311C90), a novel, selective, centrally and peripherally acting 5-HT 1D -receptor agonist is under development as an acute treatment for migraine. The tolerability, pharmacokinetics and effects on blood pressure and heart rate of multiple doses of 5 or 10 mg (5 doses administered over 24 h) were compared, in healthy adult volunteers, with those after placebo and single doses of zolmitriptan. Methods Twelve subjects participated in a randomized, balanced, crossover comparison. Plasma and urine concentrations of zolmitriptan and its metabolites, pulse rate and blood pressure were measured at intervals after drug. Ten volunteers completed the study. Results Zolmitriptan was well tolerated after single and multiple doses throughout the study. There was no evidence of significant changes in the pharmacokinetic parameters of zomitriptan or its metabolites after the last dose compared to the first, except for an expected rise in peak concentrations and a small, apparent increase in the amount of drug excreted in urine and hence in CL R . After the last 10 mg dose, mean dosing interval zolmitriptan AUC was 80.3 ng ml −1 h compared with 86.5 ng ml −1 h after the single 10 mg dose (95% CI for ratio 0.76-1.13). There was no evidence of changes in the pharmacokinetic parameters of zolmitriptan and its metabolites after 10 mg compared with 5 mg, except a small increase in zolmitriptan CL R . There were no statistically significant increases in peak systolic or diastolic blood pressure after the last doses of zolmitriptan compared to placebo or in peak blood pressure after the last dose compared to the first. There were no significant differences between blood pressure immediately before the first and last doses of each multiple dose regimen. Peak erect systolic blood pressure after the last 10 mg dose (137 mmHg ) was significantly lower than that after placebo (147 mmHg, 95% CI for difference −18, −2) and that after the last 5 mg dose (148 mmHg, 95% CI −19, −3). Conclusions Repeated doses of 5 or 10 mg zolmitriptan are well tolerated despite higher plasma concentrations than expected from single doses.
Introduction (S)-4[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl ]-2-oxazolidinone), is a novel and selective, centrally and
Migraine is a debilitating and recurring disease affecting 9-16% of the population [1] . 5-HT 1B/D receptors are peripherally acting 5-HT 1B/D receptor agonist in development for the acute treatment of migraine [5] . In animal present in the cranial circulation and agonists at these receptors, including sumatriptan and the ergot alkaloids, are models, zolmitriptan has been shown to act at these central sites in addition to its vascular effects [6] and, in this way, believed to act by causing cranial vasoconstriction and by inhibiting the release of calcitonin gene-related peptide differs from sumatriptan which does not appear to cross the blood brain barrier [4] . (CGRP) and substance P from perivascular trigeminal sensory neurones [2, 3] . More recently, 5-HT 1B/D receptors Single, oral doses of 1-50 mg zolmitriptan were generally well tolerated in healthy volunteers except for some sedation have been shown to modulate nociceptive input at the level of the trigeminal nucleus caudalis, suggesting that central after 50 mg [7] . Plasma concentrations were proportional to dose with peak values at 2-4 h after dosing and elimination sites may represent an important additional target for half-life was 2.5-3.0 h. Three metabolites were detected in man: 183C91 (N-desmethyl) is a 5HT 1B/D agonist approxi-produced a modest, transient increase in blood pressure. and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10 and 12 h after the single dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, Maximum mean rises in systolic/diastolic blood pressure after single doses of 12, 25 and 50 mg were 4/8, 9 [7] . Single, oral doses of 5 and 25 mg zolmitriptan produced a significant reduction in headache multiple doses. All urine was collected for 12 h after the single dose and 6 h after the last of the multiple doses. Pulse from moderate/severe to mild/none in 62 and 81% of patients respectively 2 h after dosing compared with 15% and blood pressure were measured and adverse events recorded pre-dose on each occasion and at intervals up to improvement in placebo recipients [8] . However, up to 36% of patients who initially responded had a recurrence of 12 h after the single dose, throughout the period of multiple dosing and for 15 h after the last dose. All supine pulse and headache in this study [8] . Patients with an incomplete response after the first dose, or whose headache recurs, may BP measurements were made after at least 10 min bed rest using a semi-automatic oscillometric method (Hewlett wish to take additional doses of zolmitriptan. Therefore, in this study, we have investigated the tolerability to, pharmacoPackard 70354A), erect blood pressure was measured after 1 min sitting followed by 2 min standing upright. Twelvekinetics and effects on blood pressure of five doses of zolmitriptan administered at intervals of 6 h over 24 h. lead ECGs were recorded and blood taken for biochemical profile and full blood count pre-dose, 12 h after the single dose and 15 h after the last of the multiple doses. ECGs Methods were also recorded continuously, by Holter monitoring, throughout each subject's time in the study unit. Subjects
Twelve healthy volunteers (10 men, 2 women; age Drug assay years; weight 58-95 kg; height 160-184 cm) were recruited from the Wellcome Employee Healthy Volunteer Panel. All Plasma was separated by centrifugation of blood samples at 3000 g for 10 min and stored at −20°C or below until volunteers were required to be in good general health, nonsmokers, taking no regular medication and with no assay. Plasma concentrations of zolmitriptan and metabolites 183C91, 1652W92 and 2161W92 were determined using a significant past medical history or abnormal findings on physical examination, full blood count, biochemical profile, manual solid phase extraction method followed by an ionexchange reverse phase h.p.l.c. system with fluorescence urinalysis, 12 lead ECG or 24 h Holter monitoring. The study was approved by the independent Wellcome Protocol detection. C 18 Bond-Eluts extraction cartridges (Anachem) were pre-washed with 1 ml acetonitrile, 0.5 ml water and Review Committee and the King's Healthcare Research Ethics Committee and all volunteers gave written informed 1 ml 0.01 m sodium formate buffer (pH 4.0). A 0.2 ml aliquot of plasma and 100 ml internal standard (890W92, 4S-consent.
4-[3 -(1-methyl -4-piperidyl )-1H-indol-5-yl ]2-oxazolidinthione) in 0.5 ml water was applied to the cartridge and Study design drawn through under low vacuum. The cartridge was then washed with 1 ml sodium formate buffer, 0.75 ml water and The study was of a randomized, balanced, 4-period crossover design with at least 1 week between occasions. On one 0.5 ml of 0.5% acetonitrile in water (v/v). Elution of the analytes of interest from the cartridge was achieved by occasion, subjects received a single, open, fasting, 10 mg oral dose of zolmitriptan. On the remaining occasions, washing the cartridge with 0.3 ml of 30% acetonitrile: 70% 0.015 m di-ammonium hydrogen orthophosphate ( pH 3.5) which were double-blind, subjects received five oral doses of either 5 or 10 mg zolmitriptan or an identical placebo (v/v). This was then transferred to an h.p.l.c. system for injection. The system comprised a Zorbax TMS column with an interval of 6 h between doses. The first and last doses were administered after an overnight fast, at approxi-(25 cm×4.6 mm i.d.), a mobile phase of 15% acetonitrile:85% 0.014 m di-ammonium hydrogen orthophosphate mately 08.00 h; other doses were taken at least 2 h after food and subjects fasted for a further 2 h after each dose. All (pH 3.0) (v/v) and an injection volume of 200 ml with a 1 ml min −1 flow rate. Fluorescence detection was at 350 nm doses were given with 200 ml water. Subjects were admitted to the study unit on the morning of dosing and stayed for using a VG Multichrom data system. The volume of each urine collection was determined and 12 h after the single dose and for 24 h after the last of the multiple doses. They were required to remain on bedrest a 20 ml aliquot taken and frozen at −20°C or below until assay. 0.4 ml of each urine sample was shaken for 10 min for 4 h after the single dose and the first and last of the multiple doses. Caffeine or alcohol-containing drinks were with 0.4 ml 1 m formic acid and 10 ml chloroform. The sample was then centrifuged at 3000 g for 10 min and 20 ml not permitted whilst in the study unit and alcohol was not permitted for 24 h before each occasion. Based on data from of the urine/formic acid mixture (equivalent to 10 ml of urine) drawn through a Bond Eluts cartridge prepared as a previous study [7] , it was estimated that 12 subjects would give 80% power to detect a 20% change in AUC at steady described above. The cartridge was washed and eluted as above except that 2% acetonitrile was used in washing and state compared to the single dose (two sided test at 5% level) and that five doses would be sufficient to achieve elution was with 0.06 ml 40% acetonitrile in 0.01 m sodium dihydrogen orthophosphate. The h.p.l.c. consisted of a kinetic steady state.
Blood samples for assay of zolmitriptan and its metabolites Zorbax SIL column (8 cm×4 mm)+guard cartridge followed by Supelcosil LC-ABZ (25 cm×4.6 mm) with a 183C91 (N-desmethyl), 1652W92 (N-oxide) and 2161W92 (indoleacetic acid) were taken pre-dose on each occasion mobile phase of (A) 5% (v/v) acetonitrile in 0.04 m sodium dihydrogen orthophosphate and (B) 60% (v/v) acetonotrile placebo, 5 mg-placebo and 10-5 mg were estimated and their 95% CIs calculated. The differences between the prein 0.04 m sodium dihydrogen orthophosphate in the ratios 0 min: A=100%, 10 min: A=80%, 15 min: A=0%, 25 min:
last-dose and pre-first-dose blood pressures were compared for each multiple dose and the differences between the peak A=100%. Fluorescence detection was at 350 nm.
A calibration curve for each analyte was constructed from blood pressure recorded 0-6 h after the last dose with that recorded 0-6 h after the first dose were also compared for the calibration sample included in the assay using the peak height ratio of analyte:internal standard. Sample peak height each formulation. For these comparisons a pooled estimate of variation was used to produce the 95% CIs. ratios were then calculated and concentrations determined from the appropriate curve. The standard curve was a linear fit with 1/concentration weighting. The calibration range Results was 2-200 ng ml −1 for all analytes in plasma and 100-5000 ng ml −1 in urine and the assay precision and bias Ten subjects completed the study. One withdrew for were <20% at the limit of quantification (2 ng ml −1 ) and personal reasons unrelated to the study having completed <15% at concentrations ≥10 ng ml −1 in plasma and three occasions; he did not receive the 10 mg multiple dose. ≥200 ng ml −1 in urine. The other subject was withdrawn after his second occasion (5 mg multiple dose) when analysis of the Holter tape Pharmacokinetic methods
showed an episode of non-sustained ventricular tachycardia lasting 5 beats, occurring just before his third dose of Pharmacokinetic analyses were performed for the single zolmitriptan (i.e. almost 6 h since the previous dose). He dose profile and after the last of the multiple doses using was asymptomatic throughout. The randomization code was Microsoft Excel v 4.0A. The observed peak plasma not broken for these subjects, or any others, during the concentration, C max , and the time to reach the peak study which remained blind until all data had been captured. concentration, t max , were taken directly from the plasma
Other adverse events were all reported as mild or moderate profiles. The area under the plasma concentration-time in severity and none was considered serious. The most profile (AUC) was estimated using the linear trapezoidal common adverse events were headaches which generally rule. After the single dose, AUC was determined up to the occurred on the afternoon of the first day of multiple dosing last measured concentration, C t , using the linear trapezoidal and the morning of the second. Two subjects reported rule and extrapolated to infinity by the addition of C t /l z , headaches on the first day of zolmitriptan multiple dosing, where l z was the terminal phase elimination rate constant both on 5 mg, whilst six subjects reported headaches after obtained by log-linear regression. After the last of the the last dose of zolmitriptan, one on 5 mg, 3 on 10 mg and multiple doses, linear trapezoidal AUC was determined for two on both doses. Headaches were reported by four 6 h (AUC(24, 30 h)). Elimination half-life, t 1/2,z , was calcusubjects on the first day of placebo and by two subjects after lated as ln(2)/l z . Apparent clearance, CL/F, and volume of the last placebo dose. Only six subjects reported other distribution, V z /F, were calculated as Dose/AUC and adverse events throughout the multiple dosing occasions, l z .CL/F respectively. Renal clearance (CL R ) was calculated usually occurring after the first or second doses; two subjects as Ae/AUC where Ae, calculated as the product of urine reported abnormal sensations of tightness or discomfort in volume and concentration, was the amount excreted in the face, neck or trunk after the single dose. urine for 12 h after the single dose and 6 h after the last of the multiple doses and AUC was determined for the same time intervals.
Pharmacokinetic parameters
As expected, peak concentrations of zolmitriptan and its Statistical methods metabolites increased by approximately 50% after the last 10 mg dose compared with the single dose ( Table 1 ). There Comparisons of pharmacokinetic parameters, except t max , after the last of the multiple 10 mg doses with those after were no differences between dosing interval AUCs for zolmitriptan or its metabolites after the last dose and AUC the single dose and between the two multiple dosing regimens were performed using ANOVA taking into account after the single dose; consequently the ratios of zolmitriptan AUC to metabolite AUCs were unchanged except for an sources of variation due to subject, occasion, dose, and the dose-occasion interaction. All parameters, except Ae, were increase for 1652W92 (mean ratio 1.24, 95% CI 1.06, 1.46). There were no differences between zolmitriptan apparent log-transformed prior to analysis and for the comparison of 5 and 10 mg doses, AUC(0, 6 h) and C max were normalised clearance and volume of distribution after five doses compared with those after the single dose (Table 1) . Urinary to a 10 mg dose. The geometric mean ratio and its 95% confidence interval (CI) were determined for each comparirecoveries of zolmitriptan and its metabolites were greater after the last dose than after the single dose with a son. For t max , differences between median values, and the 95% CI, were estimated for the 5 and 10 mg multiple doses corresponding increase in renal clearance. For urinary recovery, the mean (95% CI) increases were 3.3% (1.4, 5.2), using a method based on the Wilcoxon signed rank test.
Differences between peak blood pressures after the last of 1.3% (0.4, 2.1), 1.5% (0.3, 2.8) and 3.3% (−2.8, 9.3) for zolmitriptan, 183C91, 1652W92 and 2161W92 respectively. the multiple doses were analysed by ANOVA using the factors subject, occasion and dose and the interaction term
The corresponding mean ratios (95% CI) for renal clearance after the last dose compared to the first were 1.29 (1.12, dose.occasion. The measurement recorded before the first dose was used as a covariate. The differences 10 mg- 1.59) respectively. The elimination half-life of zolmitriptan With a half-life of 2.5 to 3.5 h it is likely that pharmacokinetic steady state has been reached after 24 h; the increase was almost 1 h longer after the last dose (Table 1) .
Steady state zolmitriptan concentrations were proportional in C max is expected for 6 hourly dosing of a drug with a half-life approximately 3 h. The lack of change in steady to dose with no significant dose-related changes in pharmacokinetic parameters except for a slightly higher CL R after state dosing interval AUC compared with that after a single dose suggest that pharmacokinetics of zolmitriptan and its 10 mg compared to 5 mg (Table 1) . There were no doserelated changes in pharmacokinetic parameters for any of metabolites are unchanged on repeat dosing, despite the small apparent prolongation of the terminal half-life for the metabolites with a dose-proportional increase in plasma concentrations (Tables 1). zolmitriptan. Total urinary recovery of zolmitriptan and metabolites increased on repeat dosing. It is unlikely this represents a Pharmacodynamic effects true increase in recovery as that implies an increase in absorption of zolmitriptan which would give higher than Compared with placebo, there were no statistically significant increases in mean peak supine SBP after each of the multiple expected plasma concentrations on repeat dosing. It is more likely to be due to an underestimate in recoveries after the dose occasions (Table 2, Figure 2 ). Erect SBP was lower after the last 10 mg dose of zolmitriptan than after placebo single dose since urine was only collected for 12 h after the single dose, when parent drug and metabolites were or 5 mg with mean (95% CI) differences of −10 mmHg (−18, −2) and −11 mmHg (−19, −3) for peak supine sometimes still quantifiable in plasma and still being excreted in urine. Even if the collection period were longer, some SBP after the last 10 mg dose compared with placebo and 5 mg respectively (Table 2 ). There was no evidence of a of the parent drug and metabolites in urine would not be quantifiable due to concentrations eventually falling below postural drop in blood pressure after zolmitriptan (Table 2 ). There were no significant differences in mean peak SBP the assay quantification limit. Drug-related material continues to be excreted in urine beyond this time but it cannot be recorded for 6 h after the first dose (i.e. between the first and second doses) compared with that recorded in the same measured accurately. This unquantified drug/metabolites can represent a few percent of the administered dose. After period after the last dose (Table 3) . Compared with placebo, diastolic blood pressure (DBP) was higher after the first and repeat dosing, plasma and urine concentrations do not fall to near the detection limit during a dosing interval, hence last doses of zolmitriptan (Figure 2) . However, there were no statistically significant increases in mean peak DBP after estimates of total recovery will be more accurate and greater than those after single doses. This apparent increase in the last dose of each multiple dose occasion (Table 2) or between the peak values after the first and last dose of each urinary recovery after the last dose compared with the first also explains the apparent increase in renal clearance, occasion (Table 3 ). There were no differences in supine or erect heart rate between occasions (Figure 2 ). There were particularly in the case of zolmitriptan. Previous data on the pharmacokinetics of the metabolites no differences in the maximum individual peak changes in SBP, DBP or postural drop after the first or last doses of of zolmitriptan were limited as assay sensitivity was less than in this study [7] . The data now suggest that, similar to zolmitriptan compared with those after placebo (Table 4) .
sumatriptan [9] , the major metabolite is the indole-acetic acid (2161W92). However concentrations of 183C91, the Discussion N-desmethyl metabolite, are approximately half those of zolmitriptan. 183C91 is a 5HT 1B/D agonist with a potency Plasma concentrations of zolmitriptan and its metabolites were similar to those reported previously [7] . Dosetwice that of zolmitriptan. It is therefore likely it will contribute to the therapeutic effect of zolmitriptan. The proportionality of plasma concentrations and doseindependence of pharmacokinetic parameters is in accord similarity of the apparent elimination half-lives of the metabolites to that of parent drug suggest their kinetics with this earlier study, which suggested dose-proportionality of plasma concentrations after single doses up to 50 mg.
are formation-rate limited. Renal clearance values for Table 2 Mean peak blood pressures and maximum postural drops (mmHg) after the last dose of zolmitriptan or placebo with mean (95% CI) differences between doses. *Positive values indicate that many subjects did not have a fall in diastolic blood pressure at any timepoint; the maximum 'drop' for these subjects was taken as the smallest increase.
Time (h) Plasma 2161W92 (ng ml zolmitriptan and the three metabolites generally exceed increase blood pressure effects. Adverse effects tended to decrease on repeat dosing but were uncommon throughout glomerular filtration rate suggesting active secretion into the renal tubule. However, the difference from glomerular the study. Similarly, the effects of zolmitriptan on blood pressure were mild. There was a small increase in blood filtration rate is small for zolmitriptan and 183C91 suggesting they undergo only limited secretion whereas this would pressure, particularly diastolic, after the first and last doses; blood pressure was not recorded frequently after the other appear more important for 1652W92 and 2161W92.
It has been reported that tolerance develops to the doses. However the differences in peak blood pressure after the last dose of each repeat dosing occasion were not cardiovascular effects of sumatriptan during a second intravenous infusion given at least 45 min after the end of an statistically significant nor was there, in general, any significant difference between pre-and post-dose readings initial 15 min dose-escalating infusion [10] . If tolerance to the cardiovascular effects of zolmitriptan were to develop after the first and last dose of each occasion. Thus there is no evidence of a significant attenuation or enhancement of during 24 h dosing, its adverse effects and effects on blood pressure might decrease. On the other hand, increased peak cardiovascular effects on repeat dosing, even taking into account the accumulation of zolmitriptan, although it must concentrations after the last dose compared to the first might be recognised that there is little evidence of any significant tachycardia on Holter tapes in apparently healthy young adults is 1-2% [17] [18] [19] . In this study, the episode which impact of zolmitriptan on blood pressure in this study. At higher doses, zolmitriptan has been shown to have a occurred about 6 h after the second dose of zolmitriptan was identified on analysing the tape after the subject had moderate vasoconstrictor effect in healthy volunteers [7, 11] and sumatriptan administration is associated with increases completed the whole occasion in which he received all five doses of zolmitriptan. The rest of the recording was in blood pressure in volunteers [12] [13] [14] [15] [16] . Consequently, it is likely that zolmitriptan does lead to a small increase in blood unremarkable and there was no evidence of ST segment changes or changes in the QT or QT c intervals before or pressure in volunteers. However, both the mean and peak individual effects are very slight at the doses in this study after the event. It is thought unlikely to have been drug-related. and probably of no clinical significance. Furthermore zolmitriptan did not increase blood pressure in patients
In conclusion, doses of zolmitriptan up to 10 mg taken 6 hourly for 24 h were tolerated well with no important being treated for an acute migraine attack [8] .
The incidence of asymptomatic, non-sustained ventricular effects on blood pressure and no other clinically significant proportional and did not change on repeated dosing. The 7 Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P.
results suggest that, in the event of symptom recurrence a
The tolerability and pharmacokinetics of the novel few hours after their first dose, patients may take further antimigraine compound 311C90 in healthy male volunteers.
doses of zolmitriptan without significant risk. 
